Juvenile idiopathic arthritis (JIA) is a new name that changed from juvenile rheumatoid arthritis (JRA) and a bunch of arthritis lesions with an unknown cause occurring in adolescents under 16 years. JIA mainly includes subtypes such as systemic juvenile idiopathic arthritis, juvenile oligoarthritis, juvenile polyarthritis, juvenile psoriatic arthritis, juvenile enthesitis-related arthritis and juvenile undifferentiated arthritis. In JIA, in addition to the extensive attack of connective tissue in the whole body, all subtypes of the immune system have intra-articular tissue immune destruction, leading to synovial inflammation, swelling, pain and stiffness, which is one of the leading causes of pediatric acquired disability. At present, it is widely believed that although the use of non-steroidal anti-inflammatory drugs (NSAIDs) cannot change the natural history of JIA, whether non-selective or selective, it is effective for the treatment as an adjuvant treatment to reduce joint stiffness and pain as well as to increase mobility. However, studies have shown that difference in efficacy between NSAIDs seems to be small. In this study, we will focus on the safety and the possible risks of different NSAIDs to growth and development in juveniles, in order to make a more advantageous choice of NSAIDs. As we all know, all medical interventions should be centered on the wishes and interests of patients, whether curative effect, economic burden, quality of life and so on. Currently, the tools to evaluate the efficacy of JIA are primarily to estimate the quality of life from the perspective of doctors, and there may be a lack of more targeted assessment instruments based on the position of patients and their relatives.
Our team has been engaged in tradition Chinese medicine and physical therapy, including pediatric massage intervention in JIA, and has accumulated some clinical experience.
The main purpose of this study will explore the core outcome set that can appraise the real needs of patients and their relatives (patient-centered), in order to improve the pertinence of future clinical research.
Jiali Yu, Dongzhimen Hospital, Beijing University of Chinese Medicine
Sheng Han, School of Pharmaceutical Science, Peking University, Beijing
Pei Chen, Beijing Anding Hospital, Capital Medical University
Tong Guo, Beijing Anding Hospital, Capital Medical University
Wei Wang, Beijing Anding Hospital, Capital Medical University
Shuang Yang, Beijing Anding Hospital, Capital Medical University
Yi Yuan, Dongzhimen Hospital, Beijing University of Chinese Medicine
Xia Li, Dongzhimen Hospital, Beijing University of Chinese Medicine
Ziqing Chen, Dongzhimen Hospital, Beijing University of Chinese Medicine
Luyao Cheng, Dongzhimen Hospital, Beijing University of Chinese Medicine
Hejing Tang, Dongzhimen Hospital, Beijing University of Chinese Medicine
Tongtong Zhang, Dongzhimen Hospital, Beijing University of Chinese Medicine
Yena Gan, Dongzhimen Hospital, Beijing University of Chinese Medicine
Ting Zhou, Dongzhimen Hospital, Beijing University of Chinese Medicine
Duoduo Li, Dongzhimen Hospital, Beijing University of Chinese Medicine
Disease Category: Child health, Rheumatology
Disease Name: Juvenile idiopathic arthritis (JIA)
Age Range: 1 - 16
Sex: Either
Nature of Intervention: Traditional Chinese Medicine
- Clinical experts
- Consumers (caregivers)
- Consumers (patients)
- Methodologists
- Researchers
- COS for clinical trials or clinical research
- Consensus meeting
- Delphi process
- Systematic review